Stabilitech Company

Oral vaccine delivery systems, Covid research. Using OraPro technology, Stabilitech’s OraPro-COVID-19 can be developed within a matter of weeks. The viral vector can be developed within days and a capsule ready for animal testing can be ready within weeks. These stages are now complete, with clinical trials due to begin, pending securing funding. Because OraPro-COVID-19 is delivered in thermally stable capsules, it can be self-administered by patients without the need for needles and healthcare professionals. The delivery mechanism eliminates the risk of potentially infected people queuing for injections, removes the need for cold-chain delivery and enables the world’s most rapid deployment of vaccines.
Technology: AgeTech Companies
Industry: Covid-19
Headquarters: United Kingdom
Employees Number: 11-50
Funding Status: Late Stage Venture
Estimated Revenue: $10M to $50M

Visit Website
info@stabilitech.com
Register and Claim Ownership